Direct-To-Consumer Pricing As A Model For Healthcare Reform

Eli Lilly’s decision to sell its obesity drug Zepbound directly to patients for $499 per month—well below the $2,000 list price—signals how pricing innovation can bypass intermediaries, expand access and sharpen the industry’s focus on value.

Healthcare must move toward transparency and accountability in both cost and quality. Direct-to-consumer pricing…